Compound: trimipramine
SMILES: N1(c2c(cccc2)CCc3c1cccc3)CC(CN(C)C)C
InChIKey: ZSCDBOWYZJWBIY-UHFFFAOYSA-N
Synonyms: trimipramine, 739-71-9, Trimeprimine, Trimeproprimine, Sapilent, beta-Methylimipramine, Trimeprimina, Trimipramina, Trimipraminum, 7162 RP, IL 6001, IL-6001, 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N,2-trimethylpropan-1-amine, RP-7162, 5-(3-(Dimethylamino)-2-methylpropyl)-10,11-dihydro-5H-dibenz(b,f)azepine, 6S082C9NDT, 5-[3-(dimethylamino)-2-methylpropyl]-10,11-dihydro-5H-dibenz[b,f]azepine, 7162-RP, 10,11-dihydro-N,N,beta-trimethyl-5H-dibenz[b,f]azepine-5-propanamine, 5-(gamma-Dimethylamino-beta-methylpropyl)-10,11-dihydro-5H-dibenzo(b,f)azepine, CHEBI:9738, DTXSID8023715, 5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N,beta-trimethyl-, 5-(gamma-dimethylamino-beta-methylpropyl)-10,11-dihydro-5H-dibenzo[b,f]azepine, 10,11 Dihydro-N,N,beta-trimethyl-5H-dibenz(b,f)azepine-5-propanamine, 5H-Dibenz(b,f)azepine, 5-(3-(dimethylamino)-2-methylpropyl)-10,11-dihydro-, 5H-Dibenz[b,f]azepine, 5-[3-(dimethylamino)-2-methylpropyl]-10,11-dihydro-, NovoTripramine, NuTrimipramine, ApoTrimip, Novo Tripramine, Nu Trimipramine, Apo Trimip, 3-(5,6-dihydrobenzo(b)(1)benzazepin-11-yl)-N,N,2-trimethylpropan-1-amine, 10,11-DIHYDRO-N,N,BETA-TRIMETHYL-5H-DIBENZ(B,F)AZEPINE-5-PROPANAMINE, Beta, Trimipramin, (3-(2-azatricyclo(9.4.0.0^(3,8))pentadeca-1(11),3(8),4,6,12,14-hexaen-2-yl)-2-methylpropyl)dimethylamine, (3-{2-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-yl}-2-methylpropyl)dimethylamine, Trimipraminneurazpharm, Trimipramin neurazpharm, RefChem:56471, DTXCID003715, N06AA06, (3-(2-azatricyclo(9.4.0.03,8)pentadeca-1(15),3,5,7,11,13-hexaen-2-yl)-2-methylpropyl)dimethylamine, 212-008-3, Surmontil, Trimeprimina [Italian], (+)-Trimipramine, Trimipraminum [INN-Latin], Trimipramina [INN-Spanish], FI 6120, 3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N,2-trimethylpropan-1-amine, Surmontyl, 2'-Metil-3'-dimetilamino-propil-5-iminodibenzile, CHEMBL644, BRN 1321466, QJ9MUH57H8, 1-(3-Dimethylamino-2-methylpropyl)-4,5-dihydro-2,3:6,7-dibenzazepine, 10,11-Dihydro-5-(3-dimethylamino-2-methylpropyl)-5H-dibenz(b,f)azepine, Trimeproprimin, 5H-Dibenz(b,f)azepine, 10,11-dihydro-5-(3-(dimethylamino)-2-methylpropyl)-, 3564-66-7, 5H-Dibenz[b,f]azepine-5-propanamine, 10,11-dihydro-N,N,.beta.-trimethyl-, (3-{2-azatricyclo[9.4.0.0,3,8]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-yl}-2-methylpropyl)dimethylamine, 5-20-08-00099 (Beilstein Handbook Reference), Trimipramine [USAN:INN:BAN], EINECS 212-008-3, Trimipramine (USAN/INN), UNII-QJ9MUH57H8, UNII-6S082C9NDT, 10633 RP, 10645 RP, 2'-Metil-3'-dimetilamino-propil-5-iminodibenzile [Italian], UNII-9K5931C1H5, 5H-DIBENZ(B,F)AZEPINE-5-PROPANAMINE, 10,11-DIHYDRO-N,N,.BETA.-TRIMETHYL-, Spectrum_001422, .beta.-Methylimipramine, Prestwick0_000806, Prestwick1_000806, Prestwick2_000806, Prestwick3_000806, Spectrum2_001530, Spectrum3_001151, Spectrum4_000759, Spectrum5_001052, TRIMIPRAMINE [MI], TRIMIPRAMINE [INN], TRIMIPRAMINE [USAN], 5H-Dibenz(b,f)azepine, 10,11-dihydro-5-(3-(dimethylamino)-2-methylpropyl)-, (+)-, 5H-Dibenz(b,f)azepine, 10,11-dihydro-5-(3-(dimethylamino)-2-methylpropyl)-, (-)-, 5H-Dibenz(b,f)azepine, 5-(3-(dimethylamino)-2-methylpropyl)-10,11-dihydro-, (+)-, TRIMIPRAMINE [VANDF], Lopac0_001156, Oprea1_375679, SCHEMBL35144, BSPBio_000671, BSPBio_002701, KBioGR_001118, KBioSS_001902, TRIMIPRAMINE [MART.], DivK1c_000093, TRIMIPRAMINE [WHO-DD], TRIMIPRAMINE, (+)-, SPBio_001320, SPBio_002592, BPBio1_000739, GTPL7317, orb1705107, SCHEMBL29373768, HY-B1213A, KBio1_000093, KBio2_001902, KBio2_004470, KBio2_007038, KBio3_002201, NINDS_000093, GLXC-06993, Trimipramine 1.0 mg/ml in Methanol, BDBM50240410, EBC-26496, STL483796, AKOS015962182, CCG-205230, DB00726, SDCCGSBI-0051123.P004, 5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N,beta-trimethyl-, (+)-, IDI1_000093, NCGC00016013-02, NCGC00016013-03, NCGC00016013-11, NCGC00162356-01, AC-15969, RP-10663, SBI-0051123.P003, AB00053646, CS-0013853, NS00000421, D00394, AB00053646_10, AB00053646_11, EN300-24410256, L000969, Q423498, BRD-A19195498-050-05-9, BRD-A19195498-050-09-1, BRD-A19195498-050-13-3, BRD-A19195498-050-14-1, 3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N,2-trimethyl-1-propanamine #, 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N,2-trimethyl-propan-1-amine, 5-(.gamma.-Dimethylamino-.beta.-methylpropyl)-10,11-dihydro-5H-dibenzo(b,f)azepine, 5H-DIBENZ(B,F)AZEPINE, 5-(3-(DIMETHYLAMINO)-2-METHYLPROPYL)-10,11-DIHYDRO-, D-, 5H-DIBENZ(B,F)AZEPINE-5-PROPANAMINE, 10,11-DIHYDRO-N,N,.BETA.-TRIMETHYL-, (+)-, 5H-DIBENZ(B,F)AZEPINE-5-PROPANAMINE, 10,11-DIHYDRO-N,N,.BETA.-TRIMETHYL-, (-)-, 5H-Dibenz[b,f]azepine-5-propanamine, 10,11-dihydro-N,N,beta.-trimethyl-, (2Z)-2-butenedioate (1:1), InChI=1/C20H26N2/c1-16(14-21(2)3)15-22-19-10-6-4-8-17(19)12-13-18-9-5-7-11-20(18)22/h4-11,16H,12-15H2,1-3H
Theoretical properties:
molecular_formula: C20H26N2
molecular_weight: 294.4 g/mol
exact_mass: 294.209598838 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 0
hydrogen_bond_acceptor_count: 2
rotatable_bond_count: 4
heavy_atom_count: 22
topological_polar_surface_area: 6.5 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
solubility: Slightly soluble
Descriptions:
pubchem: Trimipramine is a dibenzoazepine that is 10,11-dihydro-5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)-2-methylpropyl group at the nitrogen atom. It is used as an antidepressant. It has a role as an antidepressant, a xenobiotic and an environmental contaminant. It is a dibenzoazepine and a tertiary amino compound. It is functionally related to an imipramine.
chebi: A dibenzoazepine that is 10,11-dihydro-5<em>H</em>-dibenzo[<em>b,f</em>]azepine substituted by a 3-(dimethylamino)-2-methylpropyl group at the nitrogen atom. It is used as an antidepressant.
chembl: TRIMIPRAMINE is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.
wikipedia: Trimipramine, sold under the brand name Surmontil among others, is a tricyclic antidepressant (TCA) which is used to treat depression. It has also been used for its sedative, anxiolytic, and weak antipsychotic effects in the treatment of insomnia, anxiety disorders, and psychosis, respectively. The drug is described as an atypical or "second-generation" TCA because, unlike other TCAs, it seems to be a fairly weak monoamine reuptake inhibitor. Similarly to other TCAs, however, trimipramine does have antihistamine, antiserotonergic, antiadrenergic, antidopaminergic, and anticholinergic activities.